Prabhudas Lilladher's research report on Rallis India
In our recent interaction with management of RALI, they reiterated their strategy of both, capacity & portfolio expansion driven growth. Capacity is being enhanced in both domestic (formulation) and international (MPP, pendimethalin, intermediates, etc) crop protection segment. Similarly, portfolio is being enhanced by way of new product introduction, expanding crop portfolio, eyeing more co-marketing tie-ups, introducing new AIs, etc. The current focus seems to be more on topline growth rather than catapulting EBITDA margins to industry average of 17-20%. We estimate topline/ EBITDA/ APAT CAGR of 8%/21%/20% between FY20-23E.
Outlook
We are assigning target P/E multiple of 20x given ample levers for structural topline growth. Margins may continue to be volatile given the commodity nature of RALI’s key molecules. Maintain HOLD with target price of Rs 275 (Unchanged) based on 20x Sep’22 EPS of Rs 13.7.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.